NSE: AMRUTANJAN
Amrutanjan Health Care Ltd Share Price
Company information and financial fundamentals for Amrutanjan Health Care Ltd, alongside its latest NSE share price.
About Amrutanjan Health Care Ltd
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
Classification: Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals · NSE symbol: AMRUTANJAN
Company fundamentals
Figures are as reported by the company and compiled by screener.in (fetched 2026-11-03); they may lag the latest filing. Educational information, not investment advice.
Profit and loss, yearly (₹ crore)
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69 | 71 | 87 | 86 | 101 | 136 | 131 | 134 | 158 | 177 |
| Expenses | 53 | 60 | 182 | 76 | 88 | 118 | 113 | 112 | 134 | 145 |
| Operating Profit | 16 | 11 | -95 | 10 | 13 | 18 | 17 | 22 | 24 | 31 |
| OPM % | 23% | 16% | -109% | 12% | 13% | 13% | 13% | 16% | 15% | 18% |
| Other Income | -2 | 0 | 220 | 10 | 5 | 4 | 4 | 3 | 4 | 5 |
| Interest | 1 | 1 | 0 | 0 | 1 | 3 | 2 | 2 | 1 | 0 |
| Depreciation | 2 | 2 | 2 | 1 | 2 | 3 | 4 | 4 | 3 | 3 |
| Profit before tax | 11 | 9 | 123 | 19 | 15 | 16 | 15 | 19 | 24 | 33 |
| Tax % | 46% | 42% | 25% | 38% | 34% | 39% | 35% | 36% | 38% | 37% |
| Net Profit | 6 | 5 | 92 | 11 | 10 | 10 | 10 | 12 | 15 | 21 |
| EPS in Rs | — | — | 29.80 | — | — | 3.32 | 3.47 | 4.26 | 5.10 | 7.05 |
| Dividend Payout % | 32% | 45% | 19% | 40% | 45% | 45% | 43% | 38% | 34% | 27% |
Compounded growth
Balance sheet (₹ crore)
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 20 | 23 | 90 | 94 | 98 | 74 | 79 | 86 | 92 | 106 |
| Borrowings | 8 | 8 | 1 | 1 | 30 | 22 | 15 | 8 | 2 | 2 |
| Other Liabilities | 10 | 14 | 17 | 20 | 26 | 25 | 27 | 23 | 26 | 29 |
| Total Liabilities | 41 | 48 | 111 | 118 | 157 | 124 | 124 | 120 | 124 | 140 |
| Fixed Assets | 13 | 20 | 16 | 16 | 52 | 33 | 30 | 27 | 24 | 29 |
| CWIP | 3 | 3 | 2 | 7 | 0 | 1 | 1 | 1 | 4 | 1 |
| Investments | 0 | 0 | 0 | 46 | 42 | 29 | 25 | 9 | 9 | 9 |
| Other Assets | 26 | 25 | 92 | 50 | 62 | 62 | 69 | 83 | 87 | 102 |
| Total Assets | 41 | 48 | 111 | 118 | 157 | 124 | 124 | 120 | 124 | 140 |
Cash flows (₹ crore)
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 11 | 5 | 6 | 11 | 6 | 4 | 9 | 17 | 18 | 21 |
| Cash from Investing Activity | -4 | -8 | 89 | -47 | -29 | 14 | 13 | 16 | -5 | 4 |
| Cash from Financing Activity | -1 | -2 | -30 | -8 | 20 | -27 | -14 | -14 | -12 | -13 |
| Net Cash Flow | 6 | -5 | 65 | -43 | -4 | -9 | 8 | 20 | 1 | 12 |
| Free Cash Flow | 7 | -3 | 89 | 6 | -5 | -0 | 8 | 17 | 13 | 19 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 116% | 61% | -13% | 195% | 79% | 48% | 81% | 114% | 117% | 103% |
Efficiency ratios
| Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 26 | 40 | 54 | 43 | 43 | 47 | 79 | 68 | 64 | 57 |
| Inventory Days | 121 | 117 | 52 | 84 | 87 | 74 | 66 | 56 | 50 | 49 |
| Days Payable | 76 | 76 | 69 | 122 | 90 | 76 | 56 | 44 | 45 | 51 |
| Cash Conversion Cycle | 71 | 81 | 37 | 5 | 40 | 45 | 88 | 80 | 69 | 55 |
| Working Capital Days | 52 | 67 | 44 | 36 | -52 | 14 | 29 | 43 | 44 | 50 |
| ROCE % | 54% | 29% | 28% | 18% | 14% | 16% | 18% | 23% | 26% | 31% |
Shareholding pattern (%)
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 50.58% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% |
| FIIs | 1.55% | 2.34% | 2.30% | 2.30% | 2.41% | 2.38% | 2.27% | 2.17% | 2.44% | 3.47% |
| DIIs | 7.32% | 10.60% | 11.13% | 11.41% | 12.70% | 12.90% | 13.00% | 12.66% | 12.29% | 6.90% |
| Public | 40.47% | 40.50% | 40.01% | 39.75% | 38.34% | 38.16% | 38.18% | 38.61% | 38.72% | 43.08% |
| Others | 0.07% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| No. of Shareholders | 57,169 | 54,536 | 53,856 | 51,674 | 49,431 | 47,954 | 46,675 | 45,805 | 45,135 | 46,186 |
Exchange disclosures
Next results date
Amrutanjan Health Care Ltd has a board meeting for financial results listed on 2026-11-03. Companies can reschedule; check the company's own announcement. Results calendar
Shown as filed with NSE. A filing shows that something happened, not why, and says nothing about what to do.
Compare AMRUTANJAN with APOLLOHOSP →
Wondering what to do with Amrutanjan Health Care Ltd?
This page shares company information and reported fundamentals. It does not tell you whether to buy, hold or sell. For a view that takes your own holding and goal into account, ask Samjho Bhai, our portfolio review tool.
Ask Samjho Bhai about AMRUTANJAN →How this page works · New to company fundamentals? Start learning.
Key terms: Nifty 50 · Price-to-earnings ratio · Earnings per share · Dividend yield · Market capitalisation
Other Healthcare stocks in the NSE
Frequently asked questions
What is the NSE symbol for Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd trades on the NSE under the symbol AMRUTANJAN.
Where is Amrutanjan Health Care Ltd listed?
Amrutanjan Health Care Ltd is listed on the National Stock Exchange of India (NSE) under the symbol AMRUTANJAN. It is not part of the NIFTY 50 or NIFTY 500 lists this site tracks.
Should I buy Amrutanjan Health Care Ltd shares?
Market Dekho does not give buy, sell or hold recommendations and is not a SEBI-registered Research Analyst or Investment Adviser. To review a holding against your own goal and risk, you can use Samjho Bhai, or speak to a SEBI-registered adviser.
Prices are delayed and sourced from a public market-data provider; they may contain errors. This page is educational information, not investment advice.